GU Cancers 2019 | Late recurrences of nonseminomatous germ cell malignancies

Although most patients with non-seminomatous testicular cancer are known to relapse within the first 2 years of treatment, a proportion of the patients can present late relapses. Robert Huddart, MBBS, MRCP, FRCR, PhD, of The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK, stresses the importance of continuous monitoring of patients post-treatment, and highlights the need to develop better methods of late relapse detection. This video was taken at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA.